Farhad Ravandi - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Farhad Ravandi's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Farhad Ravandi
Verified
Editorial Board Member, Blood Cancer Journal
Beats
Health, Politics, Current Events , Drawing, Art, Science , Photography
I do not cover topics, which exploit or bring harm to anyone or communities.
Content
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients - Blood Cancer Journal
By Christophe Willekens, Alex Bataller, Caitlin R Rausch, Nicholas Short, Koji Sasaki, Mahesh Swaminathan, Jean-Baptiste Micol, Tapan M Kadia, Farhad Ravandi, Arnaud Pagès, Hagop Kantarjian| Nature Verified AbstractHypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar response rates and improve tolerability. It is unknown how a VEN exposure reduced to 7 days during cycles compares to standard HMA + VEN.
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia - Bone Marrow Transplantation
By Jayastu Senapati, Guillermo Garcia-Manero, Courtney DiNardo, Gautam Borthakur, Tapan M Kadia, Elias Jabbour, Nicholas Short, Hussein Abbas, Naveen Pemmaraju, Uday Popat, Sanam Loghavi, Guilin Tang, Farhad Ravandi, Hagop Kantarjian| Nature Verified Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients - Blood Cancer Journal
By Christophe Willekens, Alex Bataller, Caitlin R Rausch, Nicholas Short, Koji Sasaki, Mahesh Swaminathan, Jean-Baptiste Micol, Tapan M Kadia, Farhad Ravandi, Arnaud Pagès, Hagop Kantarjian| Nature Verified AbstractHypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar response rates and improve tolerability. It is unknown how a VEN exposure reduced to 7 days during cycles compares to standard HMA + VEN.
Company Info
Blood Cancer Journal
Hoboken, New Jersey, United States
'+1 201-748-6000